#Masld

A new study from the University of Barcelona suggests a surprising and practical breakthrough in the fight against metabolic liver disease: two well-established drugs, pemafibrate and telmisartan, can reverse fat buildup in the liver in animal models when used together, and at half-doses that still deliver strong benefits. The research, published after a careful series of experiments in diet-induced models of MASLD, underscores the growing strategy of drug repurposing—finding new uses for medications that have already proven safe in humans. For Thai readers facing rising rates of obesity, diabetes, and related metabolic illnesses, the findings offer a glimmer of hope that accessible, safer therapies could emerge sooner rather than later, especially if translated into human studies and local clinical trials.

A sweeping new analysis presented to European gastroenterology experts finds that both diet and sugary beverages may be associated with a markedly higher risk of metabolic liver disease, with diet sodas showing a striking impact. According to the lead researchers, drinking even a single daily can of a diet beverage could raise the risk of metabolic dysfunction-associated steatotic liver disease, or MASLD, by as much as 60 percent, while sugary drinks carried a roughly 50 percent higher risk. The findings also suggest that simply replacing a sugary drink with water can cut risk substantially, by about 13 to 15 percent, underscoring a straightforward public health message: water should be the default beverage for many people, especially in communities facing rising rates of liver disease.